1.
两组患者的基线资料、治疗方案及4疗程后的疗效等资料
Baseline clinical data, treatment and response after 4 courses of treatment in the two groups
| Parameters | ASCT (n=48) | Non-ASCT (n=57) | Statistic | P |
| ASCT: Autologous stem cell transplantation; ISS: International staging system; BMPC: Bone marrow plasma cells; VCD: Bortezomib+cyclophosphamide+dexamethasone; IMiDs: Immunomodulatory drugs; PI: Proteasome inhibitor; CR: Complete response; VGPR: Very good partial response; PR: Partial response; SD: Stable disease. | ||||
| Male/female | 23/25 | 31/26 | χ2=0.437 | 0.509 |
| Age (year) | 54 (38-65) | 57 (35-65) | t=-1.862 | 0.065 |
| ISS stage Ⅰ/Ⅱ/Ⅲ |
47 (97.9%) 8/17/22 |
55 (96.5) 9/21/25 |
Z=-0.044 | 0.978 |
| Durie-salmon Ⅰ/Ⅱ/Ⅲ | 6/6/36 | 8/4/45 | t=0.921 | 0.631 |
| Cr > 177 μmol/L | 7 (14.6) | 10 (17.5) | χ2=0.197 | 0.657 |
| BMPC % | 31 (0.5-96) | 26(1-84) | t=0.734 | 0.465 |
| Induction regimen | 48(100) | 57 (100) | ||
| VCD | 22 (45.8) | 30 (52.6) | ||
| Triplet IMiD+PI | 12 (25.0) | 8 (14.0) | χ2=2.364 | 0.500 |
| Change regimen | 9(18.8) | 14 (24.6) | ||
| Others | 5 (10.4) | 5 (8.8) | ||
| Efficacy after 4 cycles induction | 48(100) | 55 (96.5) | Z=-0.741 | 0.459 |
| CR | 14 (29.2) | 13 (23.6) | ||
| VGPR | 13 (27.1) | 15 (27.3) | ||
| PR | 19 (39.6) | 23 (41.8) | ||
| SD+PD | 2 (4.2) | 4 (7.3) | ||
| CR+VGPR | 27 (56.3) | 28 (50.9) | χ2=0.294 | 0.588 |
| Treatment cycles | 6(4-10) | 9(4-14) | t=-6.113 | 0.001 |
| Maintenance received | 45 (93.8) | 49 (86.0) | χ2=1.684 | 0.194 |